Biohaven, a biopharmaceutical company, experienced a significant rise in its shares following the release of positive pharmacodynamic updates for its BHV-1300 bispecific immunoglobulin G (IgG) degrader. The updates revealed that repeat dosing of BHV-1300 resulted in over 90% reductions in IgG levels.
Currently, Biohaven's shares are trading at $22.39, representing a 27% increase from previous levels. The company shared this information in an updated corporate presentation, which was included in a filing with the U.S. Securities and Exchange Commission.
According to the presentation, BHV-1300 demonstrated faster depletion of IgG in non-human primates compared to the standard-of-care efgartigimod. This development positions BHV-1300 as a potential treatment for various immune-mediated diseases.
Biohaven is leveraging its Molecular Degraders of Extracellular Proteins (MoDE) platform to develop bispecific molecules that specifically target pathologic circulating proteins. These molecules are then directed to the liver or other organ systems for degradation through the endosomal/lysosomal pathway.
The company believes that using its MoDE platform technology for therapeutic pan-IgG depletion holds significant potential for the treatment of multiple diseases.
